Home・Akcijų sąrašas・AbCellera Biologics Inc

AbCellera Biologics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

6.4 4.23

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

5.71

Max

6.55

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-34M -43M
Pardavimai	-37M 8.3M
Pelnas, tenkantis vienai akcijai	-0.14
Pelno marža	-519.122
Darbuotojai	562
EBITDA	-23M -41M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+82.94% upside

Dividendai
By Acuity
Kitas uždarbis	2026-11-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	178M 1.8B
Ankstesnė atidarymo kaina	2.17
Ankstesnė uždarymo kaina	6.4

Naujienos nuotaikos

By Acuity

47%

53%

159 / 340 reitingas Healthcare

AbCellera Biologics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-08-06 23:06; UTC

Abcellera Biologics Inc. shares are lower in after-market trading, despite earlier reaching a session high and remaining above the 20-day moving average.

2026-08-05 23:02; UTC

Social Media

News

Abcellera Biologics shares are lower in after-market hours following disappointing Q2 results, with an EPS of -$0.18 and revenue of $4.1 million.

2026-08-03 19:36; UTC

Correlated Moves

Abcellera Biologics Inc shares are higher as market sentiment improves following President Trump's cancellation of a military strike on Iran.

2026-07-31 19:33; UTC

Correlated Moves

Social Media

Abcellera Biologics Inc is declining during Friday's session, reflecting broader biotech sector weakness amid rising yields and inflation concerns.

2026-07-30 23:41; UTC

Correlated Moves

Abcellera Biologics shares are lower in after-market trading, reflecting broader market volatility following the Federal Reserve's decision to maintain interest rates.

2026-07-29 23:51; UTC

Abcellera Biologics Inc. shares were roughly flat in after-market hours, with no specific news identified. The stock is down significantly from last month's close.

2026-07-28 19:41; UTC

News

Abcellera Biologics is rising, driven by gains in the Life Sciences Tools & Services sector and positive trends in the antibody therapeutics market.

2026-07-27 19:46; UTC

Correlated Moves

Abcellera Biologics Inc shares are higher, reflecting a modest increase since Friday's close. Broader market gains may influence sentiment in life sciences.

2026-07-24 23:46; UTC

Abcellera Biologics Inc shares are higher in after-market hours, showing resilience despite recent challenges in the bond market and declining prices.

2026-07-22 20:06; UTC

Abcellera Biologics Inc shares are lower today, reflecting broader market trends amid uncertainty ahead of the Federal Reserve meeting on July 29.

2026-07-21 23:06; UTC

Correlated Moves

Abcellera Biologics shares higher in after-market trading, maintaining strong performance since Tuesday's close, despite being below its 20-day moving average.

2026-07-20 23:16; UTC

Abcellera Biologics Inc. shares are roughly flat in after-market trading, remaining about 16.33% below their 20-day moving average.

Akcijų palyginimas

Kainos pokytis

AbCellera Biologics Inc Prognozė

Kainos tikslas

By TipRanks

82.94% į viršų

12 mėnesių prognozė

Vidutinis 10.83 USD 82.94%

Aukščiausias 13 USD

Žemiausias 7 USD

Remiantis 7 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines AbCellera Biologics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

7 ratings

Pirkti

Laikyti

Parduoti

Remiantis 7 analitikų, pateikusių AbCellera Biologics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

159 / 340 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę AbCellera Biologics Inc

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.